News | Breast Density | May 22, 2019

VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification

Paper confirms adding volumetric and visual mammographic density improves risk stratification

VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification

May 22, 2019 — Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast Cancer Risk Evaluation Tool improves breast cancer risk stratification. The research suggests VolparaDensity could be used to help guide personalized medicine through risk-adapted screening.

The study, "A case-control study to add volumetric or clinical mammographic density into the Tyrer-Cuzick breast cancer risk model," was published in the May 11 issue of Journal of Breast Imaging, the official journal of the Society of Breast Imaging.

The paper used visual BI-RADS (Breast Imaging-Reporting and Data System) 4th Edition assessments from breast imaging specialists at the University of Virginia (UVA). It included 474 women who were diagnosed with invasive breast cancer alongside 2,243 controls. The results demonstrated that the addition of volumetric and visual mammographic density measures to classical risk factors improves risk stratification, increasing the number of women accurately identified at high and lower risk of breast cancer.  The Tyrer-Cuzick Tool, one of the most complete and widely used risk models, now accepts VolparaDensity volumetric breast density assessment as a validated breast density input in Version 8.

Based on the study results, researchers concluded that risk could be used to guide precision medicine through risk-adapted screening and prevention strategies. Further, they noted in the discussion that "volumetric breast density assessment has some practical advantages because it is fully automated and has excellent agreement with 3-D breast MRI [magnetic resonance imaging]."

Jack Cuzick, Ph.D., John Snow Professor of Epidemiology, director, Wolfson Institute of Preventive Medicine, and head, Centre for Cancer Prevention, stated, "Including breast density into risk models makes sense. Breast density is a strong risk factor for breast cancer, and it is largely independent of all other known risk factors. Breast density contributes as much information as all other factors combined, nearly doubling the predictive value of the risk model. Screening programs need to take this into consideration in order to develop a personalized breast care plan for each woman."

Eric J. Kraemer, M.D., radiologist at Reno Diagnostic Centers, stated, "Incorporating an objective density measure and the Tyrer-Cuzick risk model has allowed us to better personalize screening for all of our patients. Patients with a lifetime risk of greater than 20 percent are recommended for mammography and MRI screening. The personalized plan for patients with dense breasts but with lower risk includes mammography and automated breast ultrasound (ABUS). For patients that do not have dense breasts and that are at low risk of developing breast cancer, mammography continues to be the gold standard in breast cancer screening. Developing a personalized breast care for each woman depending on her specific risk factors means that we can do a better job at detecting cancer earlier, ensuring that lives are saved."

As one of the clinical applications within VolparaEnterprise, the VolparaDensity clinical application provides radiologists with automated, objective volumetric breast density assessments and a breast density category shown to correlate to BI-RADS 4th and 5th Editions. It is CE-marked and cleared by the U.S. Food and Drug Administration (FDA), Health Canada and the TGA.

For more information: www.volparasolutions.com

Reference

1. Brentnall A.R., Cohn W.F., Knaus W.A., et al. A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model. Journal of Breast Imaging, May 11, 2019. doi.org/10.1093/jbi/wbz006

Related Content

The prevalence of genetic mutations associated with breast cancer in Black and white women is the same, according to a new JAMA Oncology study of nearly 30,000 patients led by researchers in the Basser Center for BRCA at the Abramson Cancer Center.

Getty Images

News | Women's Health | June 15, 2021
June 15, 2021 — The prevalence of genetic mutations associated with breast cancer in Black and white women is the sam
The new X-ray scanner can provide detailed information about the internal makeup of rocks, which could be useful for archaeologists studying fossils or miners making decisions about which ore to use in their extraction facilities. Image courtesy of Joel Greenberg, Duke University

The new X-ray scanner can provide detailed information about the internal makeup of rocks, which could be useful for archaeologists studying fossils or miners making decisions about which ore to use in their extraction facilities. Image courtesy of Joel Greenberg, Duke University

News | X-Ray | June 10, 2021
June 10, 2021 — Engineers at Duke University have demonstrated a prot
Kathryn A. Gold, M.D., associate clinical professor at University of California San Diego School of Medicine, presented data showing an increase in people diagnosed with advanced stage breast cancer in 2020 and 2021, compared to 2019.

Kathryn A. Gold, M.D., associate clinical professor at University of California San Diego School of Medicine, presented data showing an increase in people diagnosed with advanced stage breast cancer in 2020 and 2021, compared to 2019.

News | Breast Imaging | June 08, 2021
June 8, 2021 — Reporting at the 2021 annual meeting of the American S...
The U.S. Food and Drug Administration (#FDA) approved #Aduhelm (#aducanumab) for the treatment of #Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

Getty Images

News | PET Imaging | June 07, 2021
June 7, 2021 — The U.S.
Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

News | Radiation Oncology | June 02, 2021
June 2, 2021 — A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional rad
A) Ultrasound in 28-year-old woman (B) MRI in 34-year-old woman with suspected PAS disorder. Focal area of placental tissues bulge toward imaginary lines of normal uterine contour (dash lines). Length (L) and depth (D) measurements of placental bulge also demonstrated. p = placenta; b = bladder. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

A) Ultrasound in 28-year-old woman (B) MRI in 34-year-old woman with suspected PAS disorder. Focal area of placental tissues bulge toward imaginary lines of normal uterine contour (dash lines). Length (L) and depth (D) measurements of placental bulge also demonstrated. p = placenta; b = bladder. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Ultrasound Imaging | June 01, 2021
June 1, 2021 — According to an open-access Editor's Choice article in ARRS' ...
Feature | Coronavirus (COVID-19) | May 26, 2021 | By Dave Fornell, Editor
May 26, 2021 — There are increasing reports of persistent symptoms after a patient recovers from...
The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

News | Radiation Therapy | May 21, 2021
May 21, 2021 — An experimental drug that has shown promise in protecting healthy tissue from collateral damage caused
The drug, known as Avasopasem manganese, is made by Galera Therapeutics. It acts like a natural enzyme called superoxide dismutase and converts superoxide into hydrogen peroxide. Based on its ability to "mop up" damaging superoxide molecules, which are produced by radiation treatment, the drug is currently in clinical trials to test its ability to protect mucosal tissue from the side-effect of radiotherapy.

Getty Images

News | Radiation Therapy | May 19, 2021
May 19, 2021 — A small drug molecule that appears to protect normal tissue from the damaging effects of...